Please assess the completion status of the following clinical trial:

Trial Title: Risk and Benefit Informed MTM Pharmacist Intervention in Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All adult Geisinger patients with heart failure, as identified by a validated EHR (Electonic Health Record)-based phenotype algorithm,~* Patients with a Geisinger primary care provider (PCP)~* Patients who follow with Geisinger Cardiology (at least 1 visit in past two years).~* Fulfills the specifications for arm assignment based on the results of the care gap benefit model.~Exclusion Criteria:~* Patients with a Geisinger PCP or Cardiologist in the South Central Region (part of the Geisinger Holy Spirit footprint) as MTM availability is limited in this service area.~* Patients who have indicated they do not wish to participate in research studies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High benefit, MTM (Type: EXPERIMENTAL): This arm will comprise patients with heart failure who are predicted to receive high benefit (reduction in mortality risk) by addressing open care gaps. Following randomization, they will be referred to MTM pharmacy for review of treatments in an attempt to close appropriate care gaps.
- High benefit, no MTM (Type: NO_INTERVENTION): This arm will comprise patients with heart failure who are predicted to receive high benefit (reduction in mortality risk) by addressing open care gaps. Following randomization, they will continue to receive clinical standard-of-care: regular follow-ups with Community Medicine (every 3 months) and Cardiology (every six months). Importantly, these individuals are eligible for referral to MTM at the discretion of their physicians.
- Low benefit, MTM (Type: ACTIVE_COMPARATOR): This arm will comprise patients with heart failure who are predicted to receive low benefit (reduction in mortality risk) by addressing open care gaps. They will be selected based on age, sex, and risk-matching to the High benefit, MTM arm. They will be referred to MTM pharmacy for review of treatments in an attempt to close appropriate care gaps.

Based on this trial design, predict the completion outcome and termination type (if applicable).